Taysha Gene Therapies, Inc. TSHA
4.09 USD +0.09 (+2.25%)
At closeNov 3, 2026, 4:01 PM EST
4.09 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
3.92 Day range 4.16
3.46 52-week range 7.30
- YTD
- -25.64%
- 1 year
- -8.30%
Financial health
Altman Z-Score
7.17 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C-1 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 1
Valuation
P/E -16.2×
FY 2019 5y median -2.5× FY 2025
P/S 180×
FY 2019 5y median 39.7× FY 2025
P/B 7.1×
FY 2019 5y median 6.1× FY 2025
P/FCF -18.7×
FY 2019 5y median -3.2× FY 2025
EV/EBITDA -13.5×
FY 2019 5y median -2.0× FY 2025
EV/Sales 149×
FY 2019 5y median 28.5× FY 2025
FCF Yield -5.3%
FY 2019 5y median -31.6% FY 2025
Profitability
Gross Margin 100.0%
FY 2019 5y median 100.0% FY 2025
Operating Margin -1130.6%
FY 2019 5y median -1097.6% FY 2025
Net Margin -1115.3%
FY 2019 5y median -1071.6% FY 2025
ROE -44.1%
FY 2019 5y median -148.9% FY 2025
ROIC -34.9%
FY 2019 5y median -67.2% FY 2025
ROA -31.7%
FY 2019 5y median -64.6% FY 2025
Growth (YoY)
Revenue 17.3%
FY 2019 FY 2025
Operating Income -20.8%
FY 2019 FY 2025
EPS (diluted) 5.6%
FY 2019 FY 2025
Free Cash Flow -15.0%
FY 2019 FY 2025
Financial Health
Current Ratio 12.2×
FY 2019 5y median 4.1× FY 2025
Quick Ratio 12.2×
FY 2019 5y median 4.1× FY 2025
Debt / Equity 0.1×
FY 2019 5y median 0.8× FY 2025
Net Debt / EBITDA 2.8×
FY 2019 5y median 0.8× FY 2025
Interest Coverage -1754×
FY 2019 5y median -121× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31